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Background: Engineered nanoparticles (NPs) can induce platelet activation and aggregation, 
but the mechanisms underlying these interactions are not well understood. This could be due 
in part to use of devices that study platelet function under quasi-static conditions with low 
sensitivity to measure platelet microaggregation. Therefore, in this study we investigated the 
pharmacological pathways and regulators of NP-induced platelet microaggregation under 
flow conditions at nanoscale using quartz crystal microbalance with dissipation (QCM-D) and 
compared the data thus obtained with those generated by light aggregometry.
Methods: Blood was collected from healthy volunteers, and platelet-rich plasma was 
obtained. Thrombin receptor-activating peptide, a potent stimulator of platelet function, 
and pharmacological inhibitors were used to modulate platelet microaggregation in the 
presence/absence of silica (10 nm and 50 nm) and polystyrene (23 nm) NPs. Light aggregometry 
was used to study platelet aggregation in macroscale. Optical, immunofluorescence, and scanning 
electron microscopy were also used to visualize platelet aggregates.
Results: Platelet microaggregation was enhanced by thrombin receptor-activating peptide, 
whereas prostacyclin, nitric oxide donors, acetylsalicylic acid, and phenanthroline, but not 
adenosine diphosphate (ADP) blockers, were able to inhibit platelet microaggregation. NPs 
caused platelet microaggregation, an effect not detectable by light aggregometry. NP-induced 
microaggregation was attenuated by platelet inhibitors.
Conclusion: NP-induced platelet microaggregation appears to involve classical proaggrega-
tory pathways (thromboxane A
2
-mediated and matrix metalloproteinase-2-mediated) and can 
be regulated by endogenous (prostacyclin) and pharmacological (acetylsalicylic acid, phenan-
throline, and nitric oxide donors) inhibitors of platelet function. Quartz crystal microbalance 
with dissipation, but not light aggregometry, is an appropriate method for studying NP-induced 
microaggregation. 
Keywords: platelet microaggregation, quartz crystal microbalance with dissipation, 
pharmacology, nanoparticles
Introduction
Engineered nanoparticles (NPs) are being increasingly used in industry as well as in 
medical diagnostics and drug delivery systems, resulting in human exposure.1 Acciden-
tal contact during production or use of NPs is likely to happen via different routes, such 
as ingestion, skin penetration, or inhalation. NPs could also potentially be deliberately 
introduced into circulating blood during proposed medical applications.2 Once in the 
bloodstream, NPs come into contact with a number of blood components, including 
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platelets. Platelets have long been known to play a key role in 
vascular hemostasis, and their participation in the pathogen-
esis of inflammation and thrombotic events such as myocar-
dial infarction and stroke is also well documented.3–5 Indeed, 
several antiplatelet drugs, such as acetylsalicylic acid (ASA) 
and adenosine diphosphate (ADP) receptor antagonists, have 
been used to inhibit platelet activation in vascular diseases 
associated with platelet dysfunction.6,7
We have previously found that exposure of platelets 
to engineered carbon NPs and silica NPs led to platelet 
aggregation, an effect that was partly modulated by certain 
platelet inhibitors.8,9 However, these studies were carried 
out under non-flow conditions, so this effect could have 
been underestimated. Given that use of engineered NPs 
is growing and humans are being increasingly exposed to 
these particles, their compatibility with platelets should be 
carefully evaluated.10,11 Hence, interactions between NPs and 
platelets should be tested using devices that mimic the flow 
conditions encountered in the human microvasculature.
We have recently developed an in vitro model to charac- 
terize flow-induced platelet microaggregation using a 
commercially available quartz crystal microbalance with 
dissipation (QCM-D) device. Using this approach, the 
formation of platelet microaggregates that precede the 
generation of larger platelet thrombi can be studied and 
measured in real-time in a platelet concentration-dependent, 
flow-dependent, and shear stress-dependent manner; even 
in samples containing low platelet numbers.12,13 In addi-
tion, we have recently demonstrated that NP-induced 
platelet aggregation can be detected using QCM-D at NP 
concentrations that are undetectable by flow cytometry and 
light transmission aggregometry, both of which are well-
established methods for measurement of platelet activation 
and aggregation.14,15 Although still considered the “gold 
standard” for testing platelet function, light transmission 
aggregometry is relatively non-physiological because 
separated platelets are usually stirred under low shear stress 
and only form macroaggregates after addition of agonists, 
ie, conditions that do not accurately mimic platelet adhe-
sion, activation, or aggregation in response to vessel wall 
damage.16
The objective of this work was to investigate whether 
or not this novel approach could also be used to unravel 
the pharmacology and platelet aggregation pathways that 
underlie the interactions between NPs and platelets. For 
this purpose, QCM-D was used as an analytical tool to 
monitor the effects of different platelet-modulating agents 
on NP-induced platelet microaggregation. Finally, we 
compared the data thus obtained with those acquired by 
light aggregometry.
Materials and methods
reagents
All reagents were purchased from Sigma-Aldrich (Dublin, 
Ireland) unless otherwise indicated.
characterization of NPs
Nonporous silica spheres (10 nm and 50 nm in size) and plain 
polystyrene spheres (23 nm in size) were purchased from 
Polysciences Europe GmbH (Eppelheim, Germany).
The morphology and size of the silica NPs were confirmed 
by microscopy using an Orion® Plus helium ion microscope 
(Carl Zeiss AG, Oberkochen, Germany).15 The size of the plain 
23 nm polystyrene NPs was validated using a Zetasizer® Nano 
ZS (Malvern Instruments Ltd, Malvern, UK) at 37°C with a 
DTS 1060C clear disposable zeta cell (Malvern Instruments). 
Measurements were conducted in triplicate at a concentration 
of 100 μg/mL in phosphate-buffered saline (PBS).
Blood collection and platelet isolation
Blood was collected from healthy volunteers who had not 
taken any drugs known to affect platelet function for at least 
2 weeks prior to the study. Informed consent was obtained 
from the volunteers. Platelet-rich plasma (PRP) and platelet-
poor plasma (PPP) were prepared from blood as previously 
described.17 PRP was diluted with PBS13–15 to a final concen-
tration of 210,000 platelets/μL. PPP was used as the control. 
The study was approved by the Trinity College Dublin Faculty 
of Health Sciences Research Ethics Committee.
Measurement of platelet microaggregation 
under flow using QCM-D
Platelet microaggregation was measured using an E
4
 sys-
tem (Q-Sense AB, Gothenburg, Sweden). Briefly, this 
system includes a chamber platform that holds four 
temperature-controlled and flow-controlled modules set up in 
parallel configuration attached to a peristaltic pump (IMS 935, 
Ismatec, Glattbrugg-Zurich, Switzerland). Polystyrene-coated 
(PC) quartz crystals with a fundamental frequency of 4.95 
MHz were used as sensors (Q-Sense AB). Following coat-
ing with fibrinogen (100 μg/mL), the crystals were mounted 
in the flow chamber and PRP (210,000 platelets/μL) was 
perfused at 37°C with a flow rate of 100 μL/min accord-
ing to our previous studies.12,13 Platelet microaggregation 
was monitored in real-time by Q-Sense software (QSoft
401
) 
and measured and analyzed as changes in frequency f and 
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energy dissipation D.12 PPP was used as the control. PPP 
was perfused at 100 μL/min, and changes in f and D were 
monitored for up to 30 minutes. All the following experiments 
were performed on fibrinogen-coated PC quartz crystals.
Pharmacological modulation 
of fibrinogen-induced platelet 
microaggregation
To investigate if the device was able to detect changes in 
platelet microaggregation using platelet-modulating 
agents, the effects of thrombin receptor-activating peptide 
(TRAP, 25 μM) and a number of inhibitors of platelet 
aggregation were tested. The compounds included stan-
dard inhibitors of platelet function at maximally effec-
tive concentrations, ie, ASA (100 μM), phenanthroline 
(100 μM), apyrase (250 μg/mL), 2-methylthio-AMP 
triethylammonium salt hydrate (2-MeSAMP, 100 μM), 
S-nitroso-glutathione (GSNO, 100 μM), and S-nitroso-
N-acetyl-dl-penicillamine (SNAP, 100 μM).18–20 The 
platelet-modulating agents were added prior to initiation 
of perfusion of PRP and their effects were measured for 
30 minutes. The most effective inhibitors of platelet microag-
gregation as measured by Q-CMD were selected for further 
studies to evaluate their effects on NP-induced platelet 
microaggregation.
Additional experiments were carried out with prostacyclin 
(30 nM) which was added 60 minutes after initiation of 
perfusion of PRP, and its ability to induce disaggregation 
(dissipation of platelet microaggregates) was measured for 
30 minutes.
Pharmacological modulation of 
NP-induced platelet microaggregation
To investigate the effects of different platelet inhibitors on 
NP-induced platelet microaggregation, PRP suspensions 
were perfused through the system at a flow rate of 100 μL/min 
in the presence of vehicle or NPs at the concentrations 
used in previous studies, ie, 10 nm silica NPs (25 μg/mL), 
50 nm silica NPs (200 μg/mL), and 23 nm polystyrene NPs 
(100 μg/mL).9,15 To determine if NPs could induce changes 
in f and D in the absence of platelets, PPP was used as the 
control. PPP was perfused at 100 μL/min in the presence or 
absence of NPs and changes in f and D were monitored for 
up to 30 minutes. For experiments with inhibitors of platelet 
function, the compounds were added prior to initiation of 
perfusion of PRP with NPs and their effects were measured 
for up to 30 minutes.
Optical microscopy
The formation of platelet aggregates on the crystal surface 
was studied using a BX51M reflection epifluorescence 
microscope (Olympus, Southend-on-Sea, UK). PRP samples 
in the presence or absence of NPs were perfused through the 
device in the presence or absence of modulators of platelet 
function for 30 minutes. Crystals were then taken for opti-
cal microscopy using a 10× objective. Photomicrographs 
were captured using a digital camera and Cellsense software 
(version 1.1).
Immunofluorescence microscopy
PRP samples were perfused through the device in the 
presence or absence of TRAP and ASA for 30 minutes. 
Afterward, the samples were incubated with fluorescein 
isothiocyanate-conjugated PAC-1 antibodies (BD Biosciences, 
Oxford, UK) for 30 minutes at room temperature in the dark. 
PAC-1 recognizes an epitope on the activated glycoprotein 
GPIIb/IIIa complex of activated platelets in live cells. The 
samples were then fixed with 90% ethanol, rinsed in PBS, 
and mounted on a glass slide with mounting medium.
Photomicrographs were captured using a fast, high- 
resolution XM10 camera (Soft Imaging System GmbH, 
Münster, Germany) mounted on an Olympus BX51M 
reflection epifluorescence microscope. Images were pro-
cessed using Cell-P software (Soft Imaging System).
scanning electron microscopy
For scanning electron microscopy imaging, PRP samples 
were perfused through the device in the presence or absence 
of TRAP and ASA. Afterward, the samples were fixed 
using 2.5% glutaraldehyde for 30 minutes at 37°C and then 
dehydrated through ascending grades of ethanol (60% for 
20 minutes, 80% for 20 minutes, 90% for 20 minutes, and 
finally 100% for 30 minutes, repeated once). The samples 
were then mounted on aluminum stubs and coated with 
gold/palladium (10 nm coating). Formation of platelet 
aggregates was visualized using an Ultra Plus field emission 
scanning electron microscope (Carl Zeiss AG) at 5.00 kV.
Platelet aggregation monitored by light 
aggregometry
The ability of NPs to induce platelet aggregation was 
measured using a four-channel whole blood Lumi aggregom-
eter (Chrono-Log Corporation, Havertown, PA, USA) linked 
to an Aggrolink data reduction system (810DR; Chrono-Log 
Corporation). The NPs were sonicated for 10 minutes prior 
to the aggregation assay. PRP samples were incubated in 
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the presence of vehicle or 10 nm silica NPs (25 μg/mL), 
50 nm silica NPs (200 μg/mL), or 23 nm polystyrene NPs 
(100 μg/mL), and their effects were recorded for 20 minutes. 
Collagen (5 μg/mL)-induced platelet aggregation and stirred 
platelets were used as the controls.
statistical analysis
The results are expressed as a percentage of f and D from 
the third overtone, where the maximal changes in f (negative 
shift) and D (positive shift) at 30 minutes of perfusion for the 
control (210,000 platelets/μL) are considered as 100%.12–15 
Data from at least three independent experiments were ana-
lyzed using GraphPad Prism 5 software (GraphPad Software, 
La Jolla, CA, USA). All means are reported with the stan-
dard deviation. Paired Student’s t-tests, one-way analysis 
of variance, and Dunnett’s multiple comparisons post-test 
were performed as appropriate. Statistical significance was 
considered at P,0.05.
Results
Perfusion of sensor crystals with PrP 
leads to platelet microaggregation
In the absence of modulators of platelet function, perfusion 
with PRP resulted in a decrease in f and an increase in D 
(Figure 1A), indicating deposition of platelets on the sensor 
surface as corroborated by optical microscopy (Figure 1C). 
PPP was used as the control for protein deposition on the 
surface of the crystals (Figure 1B and D). 
Pharmacological modulation of platelet 
microaggregation using QCM-D
PRP samples were perfused in the presence or absence of 
TRAP and different platelet inhibitors. TRAP enhanced D 
after 30 minutes of perfusion (Figure 2A). A cyclooxygenase 
inhibitor, ASA,21,22 was able to inhibit platelet aggregation, 
reducing the changes in both f and D when compared with 
the control (Figure 2B). The effects of ASA and TRAP on 
platelet aggregation were also corroborated by scanning 
electron microscopy and immunofluorescence microscopy, 
as shown in Figures 3 and 4.
Phenanthroline, a matrix metalloproteinase (MMP) 
inhibitor that inhibits platelet activation,23,24 also reduced 
platelet aggregation as measured by the device (Dp=0.006; 
fp=0.0014, n=7). In fact, in the presence of phenanthroline, 
smaller aggregates were observed by optical microscopy 
as compared with control. Neither apyrase (an ADP 
scavenger)20,25 nor 2-MeSAMP (a selective P2Y
12
 receptor 
antagonist)19 significantly affected platelet aggregation 
Figure 1 Quartz crystal microbalance with dissipation. Perfusion of PRP leads to platelet microaggregation. 
Notes: (A, B) representative traces for frequency f and energy dissipation D (from the third overtone) recorded by the device. Frequency is represented as a blue line and 
its values shown in the left axis. Energy dissipation is represented as a red line and its values are shown in the right axis. Perfusion of fibrinogen-coated polystyrene-coated 
quartz crystals with PrP results in platelet deposition as shown by changes in D (80) and f (-160). In contrast, perfusion with PPP leads to lower changes in D (35) and f (-80), 
reflecting protein deposition. (C, D) Representative micrographs of the surface of fibrinogen-coated polystyrene-coated quartz crystals as viewed by optical microscopy 
showing accumulation of platelet microaggregates following perfusion with PrP, but not with PPP. scale bar 20 μm.
Abbreviations: PrP, platelet-rich plasma; PPP, platelet-poor plasma.
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Figure 2 Quartz crystal microbalance with dissipation. Effects of TRAP and ASA on platelet microaggregation.
Notes: (A) Quantitative analysis of the effects of TRAP on frequency f and energy dissipation D. TRAP did not significantly change f but increased D compared with the control. 
The data are presented as the mean ± standard deviation. *P,0.05 versus control. (B) Quantitative analysis of the effects of ASA on frequency f and energy dissipation D. asa 
significantly changed f and D compared to control. The data are presented as the mean ± standard deviation. *P,0.05, **P,0.01, ***P,0.001 versus control.
Abbreviations: asa, acetylsalicylic acid; PrP, platelet-rich plasma; TraP, thrombin receptor-activating peptide.
Figure 3 scanning electron microscopy. effects of TraP and asa on platelet aggregation.
Notes: (A, B) Platelet microaggregates in the absence of any pharmacological agent as imaged by scanning electron microscopy. (C, D) Platelet microaggregates in the 
presence of TraP. (E, F) Platelet microaggregates in the presence of asa.
Abbreviations: asa, acetylsalicylic acid; PrP, platelet-rich plasma; TraP, thrombin receptor-activating peptide.
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Figure 4 Immunofluorescence microscopy. Effects of TRAP and ASA on platelet aggregation. Immunofluorescence microscopy of platelet microaggregates in the presence 
or absence of TRAP and ASA. Staining was performed with fluorescent-labelled antibodies against activated GPIIb/IIIa (PAC-1).
Notes: (A, B) Platelet microaggregates in the absence of pharmacological agents. (C, D) Platelet microaggregates in the presence of TraP. (E, F) Platelet microaggregates 
in the presence of asa.
Abbreviations: asa, acetylsalicylic acid; PrP, platelet-rich plasma; TraP, thrombin receptor-activating peptide.
(apyrase Dp=0.224; apyrase fp=0.874 and 2-MeSAMP 
Dp=0.3005; 2-MeSAMP fp=0.2198, n=4).
Since nitric oxide (NO) mediates major inhibitor path-
ways and regulates platelet GPIIb/IIIa receptor function,26–28 
we tested the effects of platelet-inhibitory NO-releasing 
agents such as SNAP29 and GSNO.30 Both compounds inhib-
ited platelet aggregation, as reflected by reduced changes 
in f and D compared with the control and corroborated by 
optical microscopy (SNAP Dp=0.0005; SNAP fp=0.0011 
and GNSO Dp=0.0005; fp=0.0017, n=4). 
Finally, because prostacyclin is the most potent endog-
enous inhibitor of platelet aggregation and stimulator of 
disaggregation,31,32 its ability to induce disaggregation was 
also tested. Prostacyclin was able to reverse changes in f and D, 
as shown in Figure 5.
characterization of NPs
The size of polystyrene and silica NPs as measured by 
dynamic light scattering and helium ion scanning microscopy 
was in agreement with the manufacturer’s specifications.
effects of NPs on platelet aggregation 
as measured by light aggregometry
Incubation of PRP with 10 nm silica NPs (25 μg/mL), 
50 nm silica NPs (200 μg/mL) and 23 nm polystyrene NPs 
(100 μg/mL) did not induce platelet aggregation as mea-
sured by the light aggregometer. However, as expected, 
incubation of platelets with the classical platelet aggregation 
agonist collagen (5 μg/mL) resulted in platelet aggregation 
(Figure 6).
effects of NPs on platelet microaggregation 
as measured by QCM-D and microscopy
Incubation of platelets with 10 nm silica NPs (25 μg/mL), 
50 nm silica NPs (200 μg/mL), and 23 nm polystyrene NPs 
(100 μg/mL) induced significant changes in f and in D as 
compared with controls. These effects were confirmed by 
optical microscopy, which showed the presence of larger 
platelet aggregates on the surface of the crystals after perfu-
sion of PRP in the presence of the NPs (Figures 7–9).
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Figure 5 Quartz crystal microbalance with dissipation. Prostacyclin-mediated inhibition of platelet activation.
Notes: Prostacyclin inhibited (A) and reversed (B) platelet microaggregation on f (blue line) and D (red line). As expected, prostacyclin exerted no significant effects on 
accumulation of plasma proteins on the sensor surface (C). green arrows indicate “prostacyclin on” and red arrows indicate “prostacyclin off”.
Abbreviations: PrP, platelet-rich plasma; PPP, platelet-poor plasma.
Figure 6 light aggregometry. effects of nanoparticles on platelet aggregation.
Notes: Incubation of PrP with (A) 10 nm silica nanoparticles (25 μg/mL), (B) 50 nm silica nanoparticles (200 μg/mL), and (C) 23 nm polystyrene nanoparticles (100 μg/mL) 
did not induce platelet aggregation (black curves). Incubation of platelets with collagen (5 μg/mL) was used as the positive control (blue curve).
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Figure 7 Quartz crystal microbalance with dissipation. Effects of 10 nm silica nanoparticles on platelet aggregation. 
Notes: (A) Quantitative analysis of the effects of perfusion of PPP and PRP in the presence or absence of 10 nm silica nanoparticles and modulators of platelet function 
on frequency and energy dissipation. The data are presented as the mean ± standard deviation. *P,0.05, **P,0.01, ***P,0.001 versus PrP. ^P,0.05, ^^P,0.01, ^^^P,0.001 
versus PrP +10 nm silica nanoparticles. (B) Representative micrographs of the surface of fibrinogen-coated PC-quartz crystals as viewed by optical microscopy showing 
platelet microaggregates following perfusion with PrP in the absence and presence of 10 nm silica nanoparticles and gsNO as an example of a pharmacological modulator 
of platelet function. scale bar 20 μm.
Abbreviations: PrP, platelet-rich plasma; PPP, platelet-poor plasma; Pc, polystyrene-coated; asa, acetylsalicylic acid; Phen, phenanthroline; gsNO, S-nitroso-glutathione; 
si, silica; sNaP, S-nitroso-N-acetyl-dl-penicillamine.
In order to know if NPs were able to induce changes in 
f and in D in the absence of platelets, PPP in the absence 
or presence of silica NPs and polystyrene NPs were also 
perfused through the crystals. No significant changes were 
found in f and in D when PPP was incubated with the NPs 
(Figures 7–9).
Pharmacological modulation of NP-induced 
platelet microaggregation: role of mediators 
and signaling pathways
Knowing that ASA, phenanthroline, GSNO, and SNAP 
were able to significantly reduce fibrinogen-induced 
platelet microaggregation, we tested these compounds on 
NP-induced platelet microaggregation. We studied the effects 
of ASA, the most commonly used antiplatelet drug, which 
inhibits generation of thromboxane A
2
 (TXA
2
) in platelets, 
on microaggregation induced by NPs. ASA reduced the 
microaggregation induced by 10 nm silica, 50 nm silica, 
and 23 nm polystyrene NPs, as detected by changes in both 
f and D (Figures 7–9). We also tested the effect of phenan-
throline, which inhibits the MMP-dependent pathway of 
aggregation, on NP-induced microaggregation. We found 
that phenanthroline failed to modify f on microaggregation 
induced by 10 nm silica NPs. In contrast, the same concentra-
tion of phenanthroline was able to reduce microaggregation 
induced by 50 nm silica and 23 nm polystyrene NPs, as shown 
by changes in both f and D (Figures 7–9). Finally, we investi-
gated the effects of GSNO and SNAP, two platelet-inhibitory 
NO-releasing agents, on NP-induced platelet microaggrega-
tion. Both inhibitors reduced NP-induced microaggregation 
as measured by changes in f and D induced by all three NPs 
tested (Figures 7–9).
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Pharmacological modulation of NP-induced platelet microaggregation
Figure 8 Quartz crystal microbalance with dissipation. Effects of 50 nm silica nanoparticles on platelet microaggregation.
Notes: (A) Quantitative analysis of the effects of perfusion of PPP and PRP in the presence or absence of 50 nm silica nanoparticles and modulators of platelet function on 
frequency and energy dissipation. The data are presented as the mean ± standard deviation. **P,0.01; ***P,0.001 versus PrP. ^^P,0.01; ^^^P,0.001 versus PrP +50 nm 
silica nanoparticles. (B) Representative micrographs of the surface of fibrinogen-coated polystyrene-quartz crystals as viewed by optical microscopy showing platelet 
microaggregates following perfusion with PrP in the absence and presence of 50 nm silica nanoparticles and Phen as an example of a pharmacological modulator of platelet 
function. scale bar 20 μm.
Abbreviations: PrP, platelet-rich plasma; PPP, platelet-poor plasma; asa, acetylsalicylic acid; Phen, phenanthroline; gsNO, S-nitroso-glutathione; si, silica; sNaP, S-nitroso-
N-acetyl-dl-penicillamine.
Discussion
Platelet activation and aggregation play an important role 
in the pathophysiology of cardiovascular diseases, such as 
stroke and myocardial infarction. It has been previously 
shown that environmental exposure to air containing NPs is 
associated with a high incidence of cardiorespiratory mor-
bidity and mortality33,34 and that engineered NPs may trigger 
platelet activation and aggregation in vitro8,9,15 and thrombus 
formation in vivo.8 Indeed, most of the research published in 
the nanotechnology-platelet field is focused on understanding 
and investigating the mechanisms involved in platelet–NP 
interactions.10 However, in some cases, these mechanisms 
are not very well characterized. This could be partly due to 
the standard use of non-flow devices in research for testing 
platelet function. In fact, there is widespread recognition of 
the need for more sensitive methods to test platelet function 
under flow conditions and in nanoscale.35 In the current study, 
we provide evidence that QCM-D is an appropriate device 
for preclinical evaluation of the biocompatibility of nano-
materials with platelets and for measuring the effects of 
standard pharmacological regulators on agonist-induced and 
NP-induced microaggregations.
Pharmacology of fibrinogen-induced 
platelet microaggregation
First, we ascertained that the QCM-D was able to detect 
changes in platelet microaggregation induced by standard 
platelet-modulating agents. TRAP is a potent proteinase- 
activated receptor agonist that activates proteinase-activated 
receptor 1 (PAR1) and downstream the ADP-dependent, 
TXA
2
-dependent, and MMP-2-dependent aggregation path-
ways.36 We found that TRAP amplified platelet microaggre-
gation as monitored by QCM-D and this was corroborated by 
microscopy. Next, we studied the pharmacological effects of 
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Figure 9 Quartz crystal microbalance with dissipation. Effects of 23 nm polystyrene nanoparticles on platelet microaggregation.
Notes: (A) Quantitative analysis of the effects of perfusion of PPP and PRP in the presence or absence of 23 nm polystyrene nanoparticles and modulators of platelet function 
on frequency and energy dissipation. The data are presented as the mean ± standard deviation. **P,0.01; ***P,0.001 versus PrP. ^P,0.05; ^^P,0.01; ^^^P,0.001 versus 
PrP +23 nm polystyrene nanoparticles. (B) Representative micrographs of the surface of fibrinogen-coated polystyrene-quartz crystals as viewed by optical microscopy 
showing platelet aggregates following perfusion with PrP in the absence and presence of 23 nm polystyrene nanoparticles and asa as an example of a pharmacological 
modulator of platelet function. scale bar 20 μm.
Abbreviations: PrP, platelet-rich plasma; PPP, platelet-poor plasma; asa, acetylsalicylic acid; Phen, phenanthroline; gsNO, S-nitroso-glutathione; si, silica; sNaP, S-nitroso-
N-acetyl-dl-penicillamine; Poly, polystyrene.
a panel of platelet inhibitors in order to evaluate the relative 
contributions of the TXA
2
-dependent, MMP-2-dependent, 
and ADP-dependent pathways to platelet microaggregation. 
We found that both ASA and phenanthroline were able to 
inhibit platelet aggregation, showing the involvement of 
TXA
2
 and MMP-2 in this process. However, apyrase and 
2-MeSAMP did not exert significant effects on platelet 
microaggregation, indicating that release of ADP from 
platelets does not significantly contribute to generation of 
platelet microaggregates under the experimental conditions 
used. Prostacyclin and NO are important platelet inhibitors 
generated from the endothelium that synergize to regulate 
platelet activation;31 therefore, prostacyclin and two NO-
releasing compounds, GSNO and SNAP, known to inhibit 
platelet aggregation,29,30 were also tested. Prostacyclin was 
not only able to inhibit platelet aggregation but also caused 
disaggregation as monitored in real-time by the device, an 
effect similar to that measured by light aggregometry.27 
We also found that GSNO and SNAP inhibited platelet 
microaggregation as measured by the device and cor-
roborated this effect by phase-contrast microscopy. Taken 
together, our results show that the QCM-D method is able 
to detect changes in platelet microaggregation induced by 
standard platelet-modulating agents. 
Pharmacology of NP-induced platelet 
microaggregation
Silica NPs and polystyrene NPs were selected to study the 
effects of NPs on platelets because they are widely used in 
industrial and pharmacological applications.37,38 In order to 
corroborate the NP characteristics as specified by their manu-
facturer, their size was evaluated prior to pharmacological 
studies. The measurements showed that the NPs did not 
diverge from the manufacturer’s specifications. This is 
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extremely important when evaluating the toxicological 
effects of NPs on biological systems, given that agglomera-
tion of NPs could, among other effects, influence cellular 
uptake39 and generation of reactive oxygen species.40
Next, we studied the effects of silica NPs and polysty-
rene NPs on platelet aggregation using light aggregometry. 
Importantly, none of the evaluated NPs, at the concentra-
tions tested, induced platelet aggregation in PRP, which 
is in agreement with our previous study.15 However, light 
aggregometry was capable of measuring platelet aggregation 
induced by collagen, and showed that platelets reacted as 
expected in the presence of a standard platelet stimulant. In 
contrast, the QCM-D was able to detect platelet microag-
gregation induced by all three types of NPs at concentra-
tions undetectable by light aggregometry. Interestingly, 
when the silica NPs were compared, the smaller NPs (10 
nm) induced more platelet microaggregation than the larger 
NPs (50 nm), as measured by changes in D. These results 
were corroborated by phase-contrast microscopy and are in 
good agreement with our previous studies.9,14,15 Importantly, 
because QMC-D is a very sensitive device and can detect 
nanograms of mass, it was investigated whether or not all 
three NPs on their own or via interactions with plasma 
proteins41 could be responsible for changes in f and D. 
However, we did not find changes in f or D when PPP was 
allowed to interact with NPs as compared with NP-free PPP, 
indicating that the changes in f and D were due to platelet 
but not NP deposition.
We then investigated whether NP-induced platelet micro-
aggregation could be inhibited by the NO donors, phenan-
throline and ASA. Platelet microaggregation induced by all 
NPs tested was inhibited by GSNO and SNAP, indicating that 
platelets exposed to NPs retain their ability to be regulated by 
pharmacological inhibitors of platelet activation. In fact, NO 
is generated by the endothelium and has the ability to main-
tain vasodilator tone and inhibit platelet function via stimu-
lation of the soluble guanylate cyclase and cGMP-induced 
reduction in intracellular calcium levels.28,42 Recently, we 
reviewed the mechanisms involved in platelet–NP interac-
tions and proposed that increased intraplatelet calcium levels 
contribute to NP-induced platelet aggregation.10 In contrast, 
decreased NO bioactivity may play a role in the pathogenesis 
of atherosclerosis and ischemic heart disease.43 
Phenanthroline, an inhibitor of the MMP-2-mediated 
pathway of platelet aggregation23 exerted differential effects 
on NP-induced platelet microaggregation by inhibiting 
reactions stimulated by polystyrene NPs and 50 nm silica 
NPs, but not those induced by 10 nm silica NPs. Indeed, 
phenanthroline failed to induce significant changes in f when 
10 nm silica NPs were allowed to interact with platelets. 
This could be explained by the fact that formation of large 
aggregates by smaller NPs, such as 10 nm silica NPs, is more 
accurately detected by changes in D.12 In fact, we have pre-
viously found that the smallest silica NPs induced the most 
severe effects on washed platelets.9 In addition, their shape 
and surface characteristics (electrochemical charge and redox 
properties) are further considerations.10
In the current experiments, ASA, a classical inhibitor 
of cyclooxygenase and the TXA
2
-dependent pathway of 
platelet aggregation and one of the drugs most frequently 
used to prevent thrombotic complications of vascular 
atherosclerosis,44 inhibited silica and polystyrene NP-induced 
platelet microaggregation. Interestingly, ASA had no signifi-
cant impact on carbon NP-induced aggregation,8 suggesting 
differential involvement of TXA
2
 in the effects mediated by 
various NPs.
What is the significance of our study? First, we dem-
onstrated that QCM-D, but not light aggregometry, is a 
very sensitive tool for detection of NP-induced platelet 
aggregation. In fact, our method detects nanograms of 
mass, and therefore platelet microaggregation, while light 
aggregometry does not. This is very important when studying 
NP–platelet interactions, given that platelet microaggregates 
produced in the early phases of platelet activation are now 
considered to potentially aggravate thrombus formation.5,45 
Second, we provide evidence that NP-induced platelet micro-
aggregation is amenable to pharmacological modulation by 
inhibitors of two major pathways of aggregation that are 
mediated via generation of TXA
2
 and MMP-2. In contrast, 
release of ADP from platelets is likely to be low under the 
conditions used because ADP blockers do not modify platelet 
microaggregation.
Finally, our study provides further evidence that preclini-
cal evaluation of the effect of NPs on platelet function should 
be considered as an essential step to ensure their design as 
non-toxic agents with optimum platelet compatibility.10
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